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Untangling BRCA mutations, sex hormones, and cancer risk
Understanding basic disease mechanisms might 
allow development of novel strategies for the primary 
prevention of breast and ovarian cancer. For carriers of 
BRCA1/2 mutations, options for primary prevention 
are limited to bilateral salpingo-oophorectomy and 
prophylactic mastectomy. In The Lancet Oncology, 
Martin Widschwendter and colleagues1 compare ovarian 
and endometrial function in carriers of the BRCA1/2 
mutation with high-risk, mutation negative women 
in the UK Familial Ovarian Cancer Screening Study. 
BRCA1/2 mutations are thought to cause cancer via a 
defect in DNA damage response or in the DNA repair 
pathway, but this does not explain organ-speciﬁ c cancer 
penetrance. These novel data suggest that end-organ 
response might have a role.
Using endometrial thickness measurements collected 
during transvaginal ultrasound to detect ovarian cancer, 
cross-sectional data showed that premenopausal 
women carrying the mutation (n=203 scans in 
116 BRCA1-positive women and 190 in 112 BRCA2-
positive women) had a thicker endometrium in the 
follicular phase and a thinner endometrium in the luteal 
phase than did controls (n=1573 scans in 754 women). 
Using existing blood samples from a small number 
of women carrying the BRCA1 (n=38) and BRCA2 
(n=32) mutations, the investigators did not identify 
any diﬀ erences in circulating concentrations of 
oestradiol and progesterone in the follicular phase, but 
concentrations of both hormones were higher in the late 
luteal phase (days 21–26) compared with 339 controls. 
The investigators propose that this relates to a defect 
in steroid-hormone regulation, which potentiates the 
mutagenic eﬀ ect of the BRCA1/2 mutation and explains 
the organ speciﬁ c penetrance of malignancies. 
An important limitation of this approach is using 
endometrial thickness as a marker of hormone regulation. 
How endometrial thickness was measured is not deﬁ ned. 
Endometrial ultrasound is highly user-dependent. 
Scans were done at 44 diﬀ erent sites but no data on 
reproducibility were reported. Normal premenopausal 
endometrial thickness varies substantially. It is increased 
during the follicular phase, plateaus around ovulation, 
and remains stable throughout the luteal phase.2 This 
variation does not support the assertion that in women 
carrying the BRCA1/2 mutation a thinner endometrium 
and higher luteal concentrations of oestradiol and 
progesterone are in complete concordance. Unlike 
exogenous progestogens, luteal progesterone does not 
typically induce a thin endometrium.3 
It is also unclear how menopausal status was deﬁ ned. 
Participants were younger than 50 years, but menstrual 
irregularity starts at a median age of 47 years, and 
participants with anovulatory cycles would have notably 
diﬀ erent endometrial thickness and circulating sex 
steroids.4 Exogenous sex steroids would also aﬀ ect all 
measures but present use was not recorded.
Higher circulating oestradiol in carriers of the gene 
mutation is consistent with general population data 
associating higher oestradiol with premenopausal 
breast cancer risk.5 The proposed relation with higher 
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Axitinib dose titration: what’s the limiting factor?
Pharmacokinetic data suggest that for patients with 
metastatic renal-cell carcinoma an increased exposure 
to tyrosine kinase inhibitors could be associated with 
improved clinical outcome.1,2 To date, four approaches 
to increase drug exposure have been proposed. 
First, simple dose escalation until unacceptable toxic 
eﬀ ects is reached (a strategy which has ultimately 
failed);3–5 second, changing the schedule from the 
beginning of treatment, or according to toxicity;6–8 
third, adapting the dose according to evidence of 
speciﬁ c polymorphisms in genes involved in drug 
pharmacokinetics;1 or, fourth, dose titration in 
progesterone concentrations is less convincing. Unlike 
testosterone levels, progesterone concentrations 
are not associated with breast cancer risk in 
premenopausal women.5 Recent pilot data suggest 
that BRCA2 carriers with breast cancer have marginally 
higher oestradiol concentrations in the early follicular 
phase than do BRCA1 or mutation negative women.6 
Preclinical data in Brca1 mice suggest increased 
circulating and endometrial proliferation in proestrus.7 
Recent data8 do not support the speculation that 
women carrying the BRCA1/2 mutation have an earlier 
age at menopause.
Combining data from carriers of the BRCA1 and 
BRCA2 mutations in the present study was justiﬁ ed 
as a measure to increase statistical power, but might 
have obscured key endocrine diﬀ erences pertinent 
to variations in cancer risks. It is unclear why a gene 
mutation aﬀ ecting DNA repair should aﬀ ect ovarian 
sex steroid production in the late luteal phase and 
this needs further investigation. Both endometrial 
and sex steroid measurements were cross-sectional, 
making it impossible to infer within-cycle sex steroid or 
endometrial diﬀ erences in BRCA carriers. 
These data are novel in combining ovarian and 
endometrial functional data in women with the BRCA1/2 
mutation. The clinical importance is the potential 
for modulating ovarian sex steroid production to 
reduce cancer risk. Ovarian suppression with the oral 
contraceptive pill reduces ovarian but not breast cancer 
risk in BRCA1/2 mutation carriers.9 It is unclear why 
exogenous sex steroids in the contraceptive pill should 
be protective, if endogenous sex steroids increase risk. 
Targeted therapies inhibiting oestrogen and HER2 are 
established in breast cancer treatment. Clarifying the 
role of progesterone might suggest a role for selective 
progesterone receptor modulators such as ulipristal.10 
It is certainly premature to suggest that sex steroids are 
one of the major drivers for development of breast cancer 
in this population. Although of interest, cross-sectional 
studies can only provide limited information on relations 
in inherently dynamic pathways. The complex relation 
between gene mutations, ovarian cancer risk, endocrine 
function, endocrine production, and receptivity in 
BRCA1/2 mutation carriers still need to be established. 
These provocative ﬁ ndings might open a new direction 
in mechanistic studies that increase understanding of 
cancer mechanisms in high-risk women.
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